2025-09-23 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the information you provided. I'll present numerical data first, followed by analysis.

## TDOC Stock Analysis Report

**Company Overview:** Teladoc Health Inc. is a virtual healthcare company that provides telehealth services.

### 1. Performance vs. S&P 500 (VOO)

*   **TDOC Cumulative Return:** -62.43%
*   **VOO Cumulative Return:** 108.04%
*   **Absolute Deviation:** -168.0
*   **Relative Deviation:** 0.4
*   **Deviation Range:** Max: 456.6, Min: -170.4

**Analysis:** TDOC has significantly underperformed the S&P 500. The current deviation is near the lowest point of its historical range, suggesting it's heavily lagging the market benchmark.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD  | Alpha  | Beta   | Cap(B) |
|------------|---------|------|--------|--------|--------|
| 2015-2017  | 76.0%   | 60.6% | 50.0%  | -0.0   | 6.3    |
| 2016-2018  | 128.0%  | 59.3% | 110.0% | -0.0   | 9.0    |
| 2017-2019  | 176.0%  | 59.3% | 147.0% | 0.4    | 15.2   |
| 2018-2020  | 237.0%  | 64.0% | 217.0% | 0.1    | 36.4   |
| 2019-2021  | -83.0%  | 64.0% | -132.0% | 0.1    | 16.7   |
| 2020-2022  | -295.0% | 81.3% | -297.0% | 0.0    | 4.3    |
| 2021-2023  | -488.0% | 81.3% | -506.0% | -0.6   | 3.9    |
| 2022-2024  | -111.0% | 81.3% | -137.0% | -0.8   | 1.6    |
| 2023-2025  | -33.0%  | 75.5% | -92.0%  | -0.8   | 1.4    |

**Analysis:**

*   **CAGR & MDD:** The table highlights periods of high growth (e.g., 2018-2020) followed by significant declines. The Maximum Drawdown (MDD) is consistently high, indicating substantial risk.
*   **Alpha:** Alpha is largely negative in recent years, indicating underperformance relative to its risk-adjusted benchmark.
*   **Beta:** Beta is generally low or negative, suggesting low correlation with the overall market.
*   **Market Cap:** Market capitalization has decreased significantly over the observed periods.

### 2. Recent Stock Price Movement

*   **Current Price:** 7.95
*   **Last-market:** {'price': 8.19, 'previousClose': 7.95, 'change': 3.02}
*   **5-day Moving Average:** 7.93
*   **20-day Moving Average:** 7.78
*   **60-day Moving Average:** 7.80

**Analysis:** The stock is trading slightly above its short-term moving averages (5-day, 20-day, and 60-day), suggesting a potential short-term upward trend.  The significant change in the 'Last-market' data (3.02%) indicates a recent positive surge.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 55.26
*   **PPO:** 0.47
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Deviation Change:** 0.4 (+) - Short-term increase
*   **Expected Return (%):** -10405.0%

**Analysis:**

*   **MRI:** The MRI suggests a "Low Risk" environment, which might be misleading given the stock's recent performance.
*   **RSI:** An RSI of 55.26 indicates a neutral to slightly bullish momentum.
*   **PPO:** A positive PPO suggests that the short-term moving average is above the long-term moving average, which may be an indication of a rising trend.
*   **Hybrid Signal:** The hybrid signal suggests a small buy with caution, aligning with the low MRI but should be carefully considered alongside other data.
*   **Recent Deviation Change:** The positive change in relative deviation hints at a possible short-term recovery.
*   **Expected Return:** The extremely negative expected return should be regarded with extreme caution, potentially indicating data anomalies or severe long-term concerns.

### 4. Recent News & Significant Events (Yahoo Finance)

*   **[2025-09-19]** Healthcare stocks: Why you should buy Doximity, not Teladoc
*   **[2025-09-17]** Berkshire Hathaway Specialty Insurance Enters the Accident & Health Market in the UK
*   **[2025-09-16]** Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
*   **[2025-09-16]** Hims & Hers Expands AI and Technology Focus to Advance Digital Care
*   **[2025-09-15]** Transcarent Appoints Dr. Alan Roga as Chief Clinical Officer
*   **[2025-09-12]** Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

**Analysis:** The news is mixed. The article suggesting to buy Doximity instead of Teladoc is concerning. The article noting Teladoc's increase despite a market slip is positive, but should be considered alongside other factors.  The news regarding competitors (Hims & Hers) expanding their digital care focus could be a competitive threat to Teladoc.

### 4-2. Analyst Opinions

*   **Analyst Consensus:** Neutral
*   **Mean Target Price:** 9.12
*   **Target Price Range:** 7.00 - 12.00

**Analysis:**  Analysts have a neutral view, with a target price slightly above the current price. This suggests a potential for moderate upside, but the lack of strong buy recommendations indicates a lack of strong conviction.

### 5. Recent Earnings Analysis:

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-07-30 | -0.19 | 0.63 B$    |
| 2025-05-01 | -0.53 | 0.63 B$    |
| 2024-10-31 | -0.19 | 0.64 B$    |
| 2024-08-01 | -4.92 | 0.64 B$    |
| 2025-07-30 | -4.92 | 0.64 B$    |

**Analysis:**

*   **EPS:** Earnings per share (EPS) has been negative in recent quarters.
*   **Revenue:** Revenue has remained relatively stable.
*   **Inconsistency:** There is a duplicate entry for '2025-07-30'.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$0.63B   | 69.85%        |
| 2025-03-31 | \$0.63B   | 68.73%        |
| 2024-12-31 | \$0.64B   | 70.50%        |
| 2024-09-30 | \$0.64B   | 71.94%        |
| 2024-06-30 | \$0.64B   | 70.73%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | \$1.42B   | -2.30%  |
| 2025-03-31 | \$1.43B   | -6.52%  |
| 2024-12-31 | \$1.49B   | -3.25%  |
| 2024-09-30 | \$1.51B   | -2.21%  |
| 2024-06-30 | \$1.50B   | -55.77% |

**Analysis:**

*   **Revenue:** Revenue is relatively consistent across quarters.
*   **Profit Margin:** Profit margins are strong, consistently around 70%.
*   **Equity:** Equity has been decreasing slightly.
*   **ROE:** Return on Equity (ROE) is negative, indicating that the company is not generating profits from its equity.

### 7. Overall Summary and Conclusion

Teladoc (TDOC) presents a mixed picture. The company has high profit margins but is struggling to generate profits, as evidenced by negative EPS and ROE. It has significantly underperformed the S&P 500, and faces increasing competition in the telehealth space.  While there is a recent short-term uptrend, the long-term outlook appears uncertain.

**Key Concerns:**

*   **Underperformance:** Significant underperformance compared to the S&P 500.
*   **Negative Profitability Metrics:** Negative EPS and ROE despite high profit margins.
*   **Competition:** Increasing competition from other telehealth providers.
*   **Analyst Sentiment:** Neutral analyst ratings.

**Potential Positives:**

*   **Short-Term Uptrend:** Recent price movement suggests a potential short-term recovery.
*   **High Profit Margins:** Strong profit margins indicate potential for future profitability.
*   **Low MRI:** Low Market Risk Indicator may be seen as a positive by some investors.

**Overall Recommendation:** Given the significant underperformance, negative profitability metrics, and mixed news, a **cautious or neutral stance** on TDOC is warranted.  Further research and monitoring are advised.

**Disclaimer:** This analysis is based solely on the data provided and should not be considered financial advice. Conduct thorough research and consult with a financial advisor before making any investment decisions.
